Eplontersen

依普隆特生

Report date: 2025/12/26 17:58:26
NME

Base Information

Drug NameEplontersen
Drug Alias NameEplontersen sodium (AstraZeneca/Ionis Pharmaceuticals)依普隆特生钠WAINUA万诺维IONIS-TTR-LRx +[8] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionTransthyretin inhibitors
TargetsTransthyretin
Therapy Area/IndicationsTransthyretin amyloidosisCardiomyopathiesAmyloid Neuropathies, Familial
Global Approved IndicationsTransthyretin amyloidosisAmyloid Neuropathies, Familial
Approved Indications in ChinaTransthyretin amyloidosis
Original Approved Country/TerritoryUnited States
Original Approved Date2023/12/21
Country/TerritoryCzechiaBelgiumCanada +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesIonis Pharmaceuticals IncAstrazeneca PlcVetter Pharma-Fertigung Gmbh & Co Kg +[5] 
Inactive CompaniesThe Brigham and Women's Hospital
Active IndicationsTransthyretin amyloidosisCardiomyopathiesAmyloid Neuropathies, Familial
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG